| Methods |
4‐week single‐blind placebo period; inclusion criteria= sitting DBP 100‐114 mm Hg after placebo period; 8‐week double‐blind treatment |
| Participants |
Lisinopril 10 mg: n=85; mean age=54 years; baseline sitting SBP=154 mm Hg, DBP=104 mm Hg, HR=77 bpm; baseline upright SBP=154 mm Hg, DBP=103 mm Hg, HR=78 bpm;
Placebo: n=81; mean age=53 years; baseline sitting SBP=155 mm Hg, DBP=103 mm Hg, HR=77 bpm; baseline upright SBP=154 mm Hg, DBP=104 mm Hg, HR=79 bpm |
| Interventions |
Lisinopril 10 mg once daily;
Placebo |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Trough upright SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported, endpoint BP reported and SEM reported; calculated endpoint SD from N and endpoint SEM; imputed endpoint SD for SD of change; BP data from Figure 1, p. 739; Jadad score=2; funding source= ICI Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
